The investigational transdermal delivery system, known as Xulane Lo, is designed to deliver 150mcg of norelgestromin and 17.5mcg of ethinyl estradiol per day.

Viatris shares favorable Phase 3 data for contraceptive patch and pain drug, affirms 2025 sales, and raises adjusted EPS ...

Lupin receives US FDA approval for raltegravir tablets USP, 600 mg: Our Bureau, Mumbai Thursday, May 8, 2025, 17:25 Hrs [IST] Global pharma major Lupin Limited (Lupin) announced t ...

Qure advances its Huntington’s program toward accelerated approval as PTC Therapeutics reports strong Phase 2 results. Learn ...

Intellia will present additional data from the ongoing Phase 1/2 study in an oral presentation at the European Academy of ...

Also in March 2025, Wave announced that the company met with the U.S. Food and Drug Administration (FDA) on WVE-N531 to ...

Operator: Good day and welcome to the CorMedix, Inc. First Quarter 2025 Financial Results Conference Call. All participants ...

Premeds can get an edge by being published several ways, from hypothesis-based research papers to conference abstracts.

State jobs are known for offering competitive benefits and enrollment in the nation’s largest public pension plan.

A common medication used to treat HIV and hepatitis B may offer unexpected protection against Alzheimer's disease.

On track to complete enrollment of the global Phase 3 HAELO study in hereditary angioedema (HAE) in the third quarter of 2025Dosed first patient in the global Phase 3 MAGNITUDE-2 study evaluating nexi ...

As part of the 10th Mediterranean Neuroscience Society Conference, we are excited to present this new collection of articles ...